Ru(II)-diphosphine/N,S-mercapto complexes and their anti-melanoma properties.

We have synthesized and characterized a novel series of ruthenium complexes with formulas [RuCl(N-S)(dppm)]PF (Ru1), [Ru(N-S)(dppm)]PF (Ru2), [Ru(N-S)(dppe)]PF (Ru3), [Ru(N-S)(dppen)]PF (Ru4), [Ru(N-S)(bpy)]PF (Ru5). In these formulas, N-S or S represents H2mq (2-mercapto-4(3)-quinazoline); dppe (1,2'-bis(diphenylphosphine)ethane), dppm (1,1'-bis(diphenylphosphine)methane), or dppen (1,2'-bis(diphenylphosphine)ethene); and bpy refers to 2,2'-bipyridine. We have also compared the cytotoxicity of cisplatin with these ruthenium complexes to murine melanoma cells (B16-F10), human melanoma cells (A-375), and the non-tumoral human keratinocyte cell line (HaCat).

Skeletal phenotypes in postmenopausal women affected by primary hyperparathyroidism.

Purpose: The current primary hyperparathyroidism (PHPT) presents as a mild disease. We explored skeletal phenotypes in postmenopausal women affected by PHPT, focusing on fracture prevalence.

Methods: PHPT women were retrospectively evaluated at four Italian centers for osteoporosis management (two centers in Milan, = 244; Cuneo, = 128; Pisa, = 131).

Pd(II)/diphosphine/curcumin complexes as potential anticancer agents.

Palladium(II) complexes have stimulated research interest mainly due to their cytotoxicity against various cancer cell lines and their low cytotoxicity in healthy cells. Thus, in this work, we combined Pd(II)/phosphine systems with the natural product curcumin as a ligand, obtaining a series of complexes, [Pd(cur)(PPh)]PF (A1), [Pd(cur)(dppe)]PF (A2), [Pd(cur)(dppp)]PF (A3), [Pd(cur)(dppb)]PF (A4) and [Pd(cur)(dppf)]PF (A5), where dppe = 1,2-bis(diphenylphosphino)ethane, dppp = 1,3-bis(diphenylphosphino)propane, dppb = 1,4-bis(diphenylphosphino)butane, and dppf = 1,1'-bis(diphenylphosphino)ferrocene (P-P), which were characterized by elemental analysis, molar conductivity analysis, and mass, NMR (H, C, P{H}), UV-vis, and IR spectroscopies, and four of them (A1, A2, A4, and A5) by X-ray crystallography. The cell viability of the complexes A1-A5, cisplatin, and the free ligand curcumin against MDA-MB-231 (human triple-negative breast tumor cells), SK-BR-3 (human breast tumor cells), A549 (human lung tumor cells), MRC-5 (non-tumor human lung cells), A2780 (human ovarian carcinoma cells), and A2780cis (cisplatin-resistant human ovarian carcinoma cells), was evaluated by the MTT colorimetric assay.